Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 9/20 | 0.72 |
| ▸ | SHBG | P04278 | 2/20 | 0.64 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.64 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.58 |
| ▸ | PGR | P06401 | 4/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.45 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17302821 | 1.00 | AR (0.72) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL6841497 | 0.88 | AR (0.71) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL6836612 | 0.88 | AR (0.71) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL13770461 | 0.88 | AR (0.59) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL13770159 | 0.88 | AR (0.59) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL13397510 | 0.88 | AR (0.59) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL7699351 | 0.87 | AR (0.70) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL6836734 | 0.87 | AR (0.70) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL7699350 | 0.87 | AR (0.70) | ARSHBGSERPINA6SLC22A1ALDH1A1 | |
| SCHEMBL6841437 | 0.87 | AR (0.70) | ARSHBGSERPINA6SLC22A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343806-B1 | METHYLENE STEROIDS AS NOVEL ANDROGENS | ORGANON NV (NL) | 2008-05-28 | — | — | EP | disclosed |
| EP-1237904-B1 | 14,15-BETA-METHYLENE SUBSTITUTED ANDROGENS | AKZO NOBEL NV (NL) | 2006-02-08 | — | — | EP | disclosed |
| US-6949531-B2 | 14 β, 16, 17-methylene steroids as novel androgens | AKZO NOBEL N.V. (NL) | 2005-09-27 | — | — | US | disclosed |
| US-6881728-B1 | 14-β, 17-α-hydroxymethylandrostane derivatives as androgens | AKZO NOBEL N.V. (NL) | 2005-04-19 | — | — | US | disclosed |
| US-20040209853-A1 | Orally active 7.alpha.-alkyl androgens | AKZO NOBEL N.V. (NL) | 2004-10-21 | — | — | US | disclosed |
| US-6780854-B2 | MALE CONTRACEPTION | AKZO NOBEL NV (NL) | 2004-08-24 | — | — | US | disclosed |
| US-6756366-B1 | 19-NORTESTOSTERONE DERIVATIVES; ORALLY ACTIVE; HIGH POTENCY | AKZO NOBEL N.V. (NL) | 2004-06-29 | — | — | US | disclosed |
| US-20040030165-A1 | 14 Beta, 16, 17-methylene steroids as novel androgens | MERCK SHARP & DOHME B.V. (NL) | 2004-02-12 | — | — | US | disclosed |
| EP-1203011-B1 | ORALLY ACTIVE ANDROGENS | AKZO NOBEL NV (NL) | 2004-01-02 | — | — | EP | disclosed |
| EP-1343806-A1 | METHYLENE STEROIDS AS NOVEL ANDROGENS | Akzo Nobel N.V. (NL) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002048171-A1 | METHYLENE STEROIDS AS NOVEL ANDROGENS | AKZO NOBEL N.V. (NL) | 2002-06-20 | — | — | WO | disclosed |
| EP-1212345-A2 | ORALLY ACTIVE 7.ALPHA.-ALKYL ANDROGENS | Akzo Nobel N.V. (NL) | 2002-06-12 | — | — | EP | disclosed |
| EP-1203011-A1 | ORALLY ACTIVE ANDROGENS | Akzo Nobel N.V. (NL) | 2002-05-08 | — | — | EP | disclosed |
| US-20020022609-A1 | Orally active androgens | LOOZEN HUBERT JAN JOZEF (NL) | 2002-02-21 | — | — | US | disclosed |
| EP-1163259-A1 | 14.BETA.,17-ALPHA-HYDROXYMETHYLANDROSTANE DERIVATIVES AS ANDROGENS | Akzo Nobel N.V. (NL) | 2001-12-19 | — | — | EP | disclosed |
| US-6313108-B1 | TREATING ANDROGEN INSUFFICIENCY | AKZO NOBEL N.V. (NL) | 2001-11-06 | — | — | US | disclosed |
| WO-2001040255-A2 | 14,15-BETA-METHYLENE SUBSTITUTED ANDROGENS | AKZO NOBEL N.V. (NL) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001005806-A1 | ORALLY ACTIVE ANDROGENS | AKZO NOBEL N.V. (NL) | 2001-01-25 | — | — | WO | disclosed |
| WO-2000059920-A2 | ORALLY ACTIVE 7.ALPHA.-ALKYL ANDROGENS | AKZO NOBEL N.V. (NL) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000053619-A1 | 14.BETA., 17-ALPHA-HYDROXYMETHYLANDROSTANE DERIVATIVES AS ANDROGENS | AKZO NOBEL N.V. (NL) | 2000-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030165-A1 | 14 Beta, 16, 17-methylene steroids as novel androgens | CYP17A1, HSD17B7, AR | AR 3/4885SHBG 15/4885SERPINA6 194/4885 |
| US-20020022609-A1 | Orally active androgens | NR5A1, AR, CYP17A1 | AR 2/4885SHBG 8/4885SERPINA6 274/4885 |
| US-20040209853-A1 | Orally active 7.alpha.-alkyl androgens | NR5A1, AR, SHBG | AR 2/4885SHBG 3/4885SERPINA6 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.